Yeah, I've seen reverse head & shoulders like 3 times in the last year, and none have panned out.
Ask Hugh, he is the H&S guru!
T.A. has its pluses and minuses, but, as mentioned before, we've had a cup and now handle pattern on the chart, starting about the second week in April. Handle is almost done, probably. Next week is the big move?
Patience...the stock will move when it's ready. It's slowly being transferred to stronger hands now.
Yes, less than one month away. Big money will pile in. They are trying to find cheap shares, but they'll have to bid up the price soon to get all they want. Strong hands aren't giving away shares.
Based on the action here over the last week, there are still more buyers than sellers. They're trying to sucker us into selling. it's not working thus far...
I'm hoping that by the time WM final results are out in December, we will have so much optimism regarding -2055 collaboration trial and new GSO candidates that the WM 8400 trial results aren't make-or-break for the company, a de-risking somewhat...
As I said before, they're smart, and wouldn't be throwing good money after bad if it were futile.
I don't want to jinx things, but I think the days of $0.30's are over. Every day they've tried to push this lower and have given up and bought at the end of the day. A big buyer (or many) want in, and they aren't gonna wait forever.
Dizziness as a good thing means that the drug enters the CNS/brain. Some drugs don't cross the blood/brain barrier, which would be the kiss of death for this drug!
If it's doing so well that it's been approved for compassionate use, we could breakthrough designation soon. Or the biggest of them all-- an early termination of the trial due to overwhelming efficacy (very very rare).
...the new cohort group for the treatment of Waldenstrom's isn't part of the trial at all? Just a compassionate usage group, due to the request of the Waldenstrom society, who have seen great results thus far...
Here's an off-the-wall idea: the new cohort isn't even using 8400... they'll be using 9200!!! Idera realizes that 9200 is vastly superior, and just wants to confirm it in direct head-to-head with 8400, behind the scenes, except that the society spilled the beans and announced the new cohort! So in a few months Idera surprise announces that all the new trials--DMD, GVHD, etc will be with 9200 instead!!! Lol!!
This should be an interesting week, ctixers. There was a standoff last week, as holders refused to give up many shares. Does the cat and mouse game continue? I think new money will have no choice but to bid up the price for their shares.
I think it's a good sign in light of our current experienced management. If WM trial wasn't going well, why add an additional cohort and throw good money after bad?? Doesn't make sense when you have a lot of other places to spend money.
it could be the opposite.. More side effects at highest dosage, but so effective, even at 0.6 my, that they want to try 0.3 mg
The market is this sense is like the blackjack table. Sometimes the cards remaining in the deck favor the player, and that's when the odds are in your favor and you should increase your bet.
In this case, the deck is in our favor, with an overlooked stock that has an irrationally low market cap. Years worth of Alzheimer trial failures have contributed to this. Ironically, it was Biogen's recent positive early data than re-ignited interest in Alzheimer's and helped move AVXL's stock price.